AnaptysBio Inc (ANAB) Shares Bought by Great West Life Assurance Co. Can
Great West Life Assurance Co. Can increased its holdings in AnaptysBio Inc (NASDAQ:ANAB) by 65.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,057 shares of the biotechnology company’s stock after purchasing an additional 817 shares during the period. Great West Life Assurance Co. Can’s holdings in AnaptysBio were worth $146,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of ANAB. SG Americas Securities LLC purchased a new position in AnaptysBio in the 1st quarter worth approximately $173,000. Quantitative Systematic Strategies LLC purchased a new position in AnaptysBio in the 2nd quarter worth approximately $211,000. Teacher Retirement System of Texas lifted its holdings in AnaptysBio by 28.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 3,335 shares of the biotechnology company’s stock worth $237,000 after purchasing an additional 743 shares in the last quarter. Xact Kapitalforvaltning AB purchased a new position in AnaptysBio in the 2nd quarter worth approximately $242,000. Finally, Creative Planning purchased a new position in AnaptysBio in the 2nd quarter worth approximately $257,000.
ANAB has been the topic of a number of research analyst reports. ValuEngine raised AnaptysBio from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Credit Suisse Group initiated coverage on AnaptysBio in a report on Thursday, July 19th. They issued an “outperform” rating and a $104.00 price target on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $121.00 price target on shares of AnaptysBio in a report on Tuesday, August 7th. Royal Bank of Canada reissued a “hold” rating and issued a $84.00 price target on shares of AnaptysBio in a report on Wednesday, August 8th. Finally, Zacks Investment Research raised AnaptysBio from a “hold” rating to a “buy” rating and set a $93.00 price objective on the stock in a report on Monday, August 13th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $125.00.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.70) by $0.13. sell-side analysts expect that AnaptysBio Inc will post -2.69 earnings per share for the current fiscal year.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Further Reading: Marijuana Stocks Investing Considerations
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.